Impact of adjuvant imatinib on bone and muscle density in patients with resected gastrointestinal stromal tumors

Data from a retrospective study of patients with surgically resected gastrointestinal stromal tumors demonstrated that those who had completed 3 years of adjuvant imatinib therapy experienced increased bone mineral density while on treatment (P = 0.021), with an even higher increase in patients with basal values less than 120 mg/cm³ (P = 0.002). However, no changes were observed among patients who did not receive imatinib treatment (P = 0.918).